QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Dose-escalation Clinical Study of QH103 Cell Injection (CD19 CAR-γδT Cell Injection) in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06056752
• Other study ID #: QH10302-B-01(0)
• Status: Recruiting
• Phase: Phase 1
• Start date: September 27, 2023
• Est. completion date: July 3, 2026

Study information

• Verified date: October 2023
• Source: Anhui Provincial Hospital
• Contact: Xiaoyu Zhu, Ph.D
• Phone: +86 15255456091
• Email: xiaoyuz[@]ustc.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Description:

To evaluate the safety and tolerability of QH103 Cell Injection in the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia, and to evaluate dose-limiting toxicity and maximum tolerated dose.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: July 3, 2026
• Est. primary completion date: July 3, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

1. Age =14 years, gender is not limited;

2. Patients with clinically diagnosed relapsed/refractory B-ALL (except those presenting with extramedullary disease only), including any of the following:

1. Failure to obtain CR after 2 cycles of standard chemotherapy;

2. First induction of CR, but duration of CR is =12 months;

3. Relapsed/refractory B-ALL that has failed to respond to the first or multiple salvage treatments;

4. Relapse after hematopoietic stem cell transplantation, including hematological relapse and positive micro residual disease (MRD).

3. Cytological or histological confirmation of tumor cell immunophenotyping as CD19 positive;

4. Bone marrow with a ratio of =5% primitive/naïve lymphocytes (morphology);

5. Expected survival time of more than 3 months;

6. Eastern Cooperative Oncology Group (ECOG) score of 0-2;

7. Vital organ function meets the following requirements: left ventricular ejection fraction =50% on echocardiography; serum creatinine=1.5 × upper limit of normal range (ULN); glutamine aminotransferase, aspartate aminotransferase =3 times ULN, total bilirubin =1.5 times ULN;

8. Pregnancy tests for women of childbearing age should be negative, and both men and women should agree to use effective contraception during treatment and for the following 1 year.

9. Toxicity of prior antitumor therapy = grade 1 (according to CTCAE version 5.0) or acceptable inclusion/exclusion criteria level.

10. No significant hereditary disease;

11. Be able to understand the requirements and matters of the trial and be willing to participate in the clinical study as required;

12. Sign the trial informed consent form.

Exclusion Criteria:

1. with uncontrolled active central nervous system leukemia (CNSL) or a history of epilepsy, cerebrovascular disease

2. Pregnant or lactating women, or those who do not consent to the use of the drug during and within 1 year after treatment;

3. Other malignant tumors not in remission;

4. with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy;

5. Patients who have received immune cell therapy within 6 months prior to enrollment and donor lymphocyte infusion within 6 weeks prior to enrollment.

6. Patients with confirmed positive serum anti-FMC63 and DSA reactions;

7. Patients who have participated in other clinical trials within 4 weeks prior to enrollment;

8. Uncontrolled infectious or other serious diseases, including but not limited to infections (Human Immunodeficiency Virus, acute or chronic active hepatitis B or hepatitis C), congestive heart failure, unstable angina pectoris cardiac arrhythmias, or conditions that the attending physician considers to be an unpredictable risk;

9. Uncontrollable plasma fluid, such as large pleural effusions or ascites;

10. History of stroke or intracranial hemorrhage within 3 months prior to enrollment;

11. Major surgery or trauma within 28 days prior to enrollment, or major side effects from which you have not recovered;

12. History of allergy to any of the ingredients in the cellular product;

13. Inability to understand or unwillingness to sign the informed consent form;

14. Other reasons deemed by the investigator to be unsuitable for the clinical trial.

Related Conditions & MeSH terms

• B-cell Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• QH103 Cell Injection
dose escalation (3+3) : dose 1 (3×10^8CAR+cells) ,dose 2 (1 × 10^9 CAR+cells),dose 3 (3 × 10^9CAR+cells)

Drug:
• Fludarabine
Intravenous fludarabine on days-5~-2,the infusion dose is adjusted according to the subject's condition
• Cyclophosphamide
Intravenous cyclophosphamide on days -5~-3, the infusion dose is adjusted according to the subject's condition

Locations

Country	Name	City	State
China	Anhui Provincial Hospital	Hefei	Anhui

Sponsors (1)

Lead Sponsor	Collaborator
Anhui Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events (AEs)	AE is defined as any adverse medical event from the date of leukapheresis to 12 months after QH103 infusion. Among them, cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria, graft-versushost disease (GVHD) according to criteria defined by the Mount Sinai Acute GVHD International Consortium. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0	12 months
Primary	Incidence of Dose-Limiting Toxicities (DLTs)	DLT was defined as QH103 Cells-related events with onset within first 28 days following infusion: The development of Grade (G) III-IV acute GVHD according to the Mount Sinai Acute GVHD International Consortium criteria; The development of G3 or higher grade CRS lasting > 2 weeks; Any QH103 cells-related AE requiring intubation; All G4 non-hematologic toxicities. Symptoms of GVHD include but are not limited to skin rash, enterocolitis with diarrhea, liver dysfunction with jaundice, fever, weight loss, etc.	First infusion date of QH103 cells to 28 days end cell infusion
Primary	Maximum tolerated dose (MTD)	MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.	28 days
Secondary	Overall Survival (OS)	OS is defined as the time from QH103 cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.	12 months
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from the QH103 cells infusion date to the date of disease progression assessed by investigators assessment, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.	12 months
Secondary	Pharmacokinetics: Persistence of the QH103 cells	Persistence of the QH103 cells assessed by number in peripheral blood.	28 days
Secondary	Pharmacodynamics: Peak level of cytokines in serum	The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-a (TNF-a) etc. Peak was defined as the maximum post-baseline level of the cytokine.	28 days
Secondary	Overall Response Rate(ORR)	Proportion of subjects with CR (complete response) and CRi (complete response with incomplete hemocyte recovery)	12 months